Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case-control analysis
Bria J Rice1, Matthew R Buras2, Heidi E Kosiorek2
1Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Aim:
We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control.
Patients & Methods:
Patients with lymphoma with and without diabetes (2005-2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan-Meier method. Hemoglobin A1c (HbA1c) and glucose levels during the year after cancer diagnosis were compared by mixed models.
Results:
For patients with diabetes, mean HbA1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53-76%) versus 58% (95% CI: 46-71%) (p = 0.42).
Conclusion:
Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Cancer Survival Analysis
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
Psychoneuroimmunology: Diabetes and Cancer
